SC 13G/A: An amendment to the SC 13G filing
Allogene Therapeutics, Inc.
Allogene Therapeutics Announces Participation in the Goldman Sachs Cell Therapy Day Conference
SOUTH SAN FRANCISCO, Calif. , Sept. 30, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products…
Allogene Therapeutics to Present Pre-Clinical Data Highlighting the Potential of ALLO-329, an Allogeneic CD19/CD70 Dual CAR T for the Treatment of Autoimmune Diseases, at the American College of Rheumatology (ACR) Convergence
The CD19/CD70 Dual CAR is Specifically Designed to Address Both the B-cell and T-cell Dysfunction Implicated in Autoimmune Diseases ALLO-329, is an Investigational Product Built on a New Gene Editing…